Impact of Brokerage Rating on Clovis Oncology, Inc.(CLVS)

Many Clovis Oncology, Inc.(CLVS) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Clovis Oncology Inc was Downgraded by Chardan Capital Markets on Feb 3, 2017 to Sell, Price Target of the shares are set at $36.Clovis Oncology Inc was Initiated by BofA/Merrill on Jan 27, 2017 to Buy, Price Target of the shares are set at $74.Clovis Oncology Inc was Upgraded by Piper Jaffray to Overweight on Jan 26, 2017. Company shares were Reiterated by Stifel on Jan 23, 2017 to Buy, Raises Price Target to $ 86 from a previous price target of $52 .Clovis Oncology Inc was Initiated by Morgan Stanley to Overweight on Jan 13, 2017.

Company has reported several Insider transactions to the SEC, on Nov 3, 2015, Erle T Mast (Executive VP and CFO) sold 3,000 shares at 104.18 per share price.On Oct 30, 2015, Lindsey Rolfe (officer ) sold 4,000 shares at 97.80 per share price.On Oct 16, 2015, Gillian C Ivers-read (officer ) sold 3,000 shares at 91.91 per share price.

Clovis Oncology Inc Last issued its quarterly earnings results on Nov 3, 2016. The company reported $-1.70 EPS for the quarter, beating the analyst consensus estimate by $ 0.25. Analyst had a consensus of $-1.95.During the same quarter in the previous year, the company posted $-2.62 EPS.

Clovis Oncology, Inc. (NASDAQ:CLVS) has received a short term rating of hold from experts at Zacks with a rank of 3. The stock has been rated an average of 2.14 by 7 Brokerage Firm. 4 Wall Street Firms have rated the stock as a strong buys. 2 Brokerage Firms have advised hold. 1 Analysts have rated it as strong sell.

Clovis Oncology, Inc. (NASDAQ:CLVS) stock has received a short term price target of $ 63.71 from 7 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $20.07. The higher estimate of target price is $86 , while the lower price target estimate is $36

Clovis Oncology, Inc. (NASDAQ:CLVS) rose 0.82% or 0.51 points on Tuesday and made its way into the gainers of the day. After trading began at $61.85 the stock was seen hitting $62.79 as a peak level and $61.4 as the lowest level. The stock ended up at $62.6. The daily volume was measured at 959,234 shares. The 52-week high of the share price is $67.16 and the 52-week low is $11.57. The company has a market cap of $2,775 million.

Clovis Oncology Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, Europe and additional international markets. The Company targets its development programs for the treatment of specific subsets of cancer populations. Clovis Oncology Inc. is headquartered in Colorado, USA.

Clovis

Share this post

Leave a Reply